Clinical Outcome of Gastric Cancer Patients with Bone Marrow MetastasesKim H.S.a · Yi S.Y.a · Jun H.J.a · Lee J.a · Park J.O.a · Park Y.S.a · Jang J.a · Kim H.-J.b · Ko Y.c · Lim H.Y.a · Kang W.K.a
aDivision of Hematology/Oncology, Department of Medicine, and Departments of bLaboratory Medicine and cPathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Gastric cancer with bone marrow metastases is known to pursue a rapidly deteriorating clinical course. We conducted a retrospective analysis to evaluate clinical manifestations and prognosis of gastric cancer patients with bone marrow metastases. Methods: Between September 1994 and February 2006, 39 gastric cancer patients with pathologically confirmed bone marrow dissemination were selected. Results: The majority of the patients showed younger age, poorly differentiated adenocarcinoma or signet ring cell carcinoma, thrombocytopenia, anemia, elevated lactate dehydrogenase and alkaline phosphatase. Poor prognostic factors for survival were serum sodium ≤133 mmol/l [relative risk (RR) 4.57; 95% CI 1.99–10.52; p < 0.001], the presence of lung metastasis (RR 3.47; 95% CI 1.48–8.15; p = 0.007) and the presence of peritoneal seeding (RR 2.17; 95% CI 1.06–4.43; p = 0.036). Median survival durations after bone marrow metastases for patients without any adverse factors (n = 19, 48.7%) and those with 1–3 adverse factors (n = 20, 51.3%) were 67 and 23 days, respectively (p = 0.013). Patients without any adverse factors did benefit from palliative chemotherapy (p = 0.048). Conclusion: We suggest that gastric cancer patients with bone marrow metastases should receive more tailored therapies according to different risk factors in order to enhance survival.
© 2008 S. Karger AG, Basel
- Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1–9.
Shin HR, Jung KW, Won YJ, Park JG, 139 KCCR-affiliated Hospitals: 2002 annual report of the Korea central cancer registry: based on registered data from 139 hospitals. Cancer Res Treat 2004;36:103–114.
- Anner RM, Drewinko B: Frequency and significance of bone marrow involvement by metastatic solid tumors. Cancer 1977;39:1337–1344.
- Johnston AD: Pathology of metastatic tumors in bone. Clin Orthop Relat Res 1970;73:8–32.
- Miric A, Banks M, Allen D, Feighan J, Petersilge CA, Carter JR, Makley JT: Cortical metastatic lesions of the appendicular skeleton from tumors of known primary origin. J Surg Oncol 1998;67:255–260.
- Hayes DF: Prognostic and predictive factors revisited. Breast 2005;14:493–499.
- Kobayashi M, Okabayashi T, Sano T, Araki K: Metastatic bone cancer as a recurrence of early gastric cancer – characteristics and possible mechanisms. World J Gastroenterol 2005;11:5587–5591.
- Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B: Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003;21:3469–3478.
- Kusumoto H, Haraguchi M, Nozuka Y, Oda Y, Tsuneyoshi M, Iguchi H: Characteristic features of disseminated carcinomatosis of the bone marrow due to gastric cancer: the pathogenesis of bone destruction. Oncol Rep 2006;16:735–740.
- Tokar M, Bobilev D, Ariad S, Geffen DB: Disseminated intravascular coagulation at presentation of advanced gastric cancer. Isr Med Assoc J 2006;8:853–855.
- Lee J, Lim T, Uhm J, Park K, Park S, Lee S, Park J, Park Y, Lim H, Sohn T, Noh J, Heo J, Park C, Kim S, Kang W: Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007;18:886–891.
- Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer – pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395–2403.
- Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois Y, Vignal J, Gilly FN: Peritoneal carcinomatosis from non-gynecologic malignancies: results of the evocape 1 multicentric prospective study. Cancer 2000;88:358–363.
- Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK: Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 2008;61:301–307.
- Batson OV: The function of the vertebral veins and their role in the spread of metastases. 1940. Clin Orthop Relat Res 1995:4–9.
- Campling B, Quirt I, DeBoer G, Feld R, Shepherd FA, Evans WK: Is bone marrow examination in small-cell lung cancer really necessary? Ann Intern Med 1986;105:508–512.
- Bezwoda WR, Lewis D, Livini N: Bone marrow involvement in anaplastic small cell lung cancer. Diagnosis, hematologic features, and prognostic implications. Cancer 1986;58:1762–1765.
- Jonsson U, Rundles RW: Tumor metastases in bone marrow. Blood 1951;6:16–25.
- Tritz DB, Doll DC, Ringenberg QS, Anderson S, Madsen R, Perry MC, Yarbro JW: Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables. Cancer 1989;63:763–766.
- Chernow B, Wallner SF: Variables predictive of bone marrow metastasis. Cancer 1978;42:2373–2378.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.